课题基金 / 基金详情

Cyp46A1 as a novel therapeutic target in prion diseases

Cyp46A1 as a novel therapeutic target in prion diseases
Cyp46A1作为朊病毒疾病的新治疗靶点
批准号：
436100
负责人：
Ali Tahir
金额：
$10.2万
依托单位：
University of Calgary
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2020
资助国家：
加拿大
项目状态：
已结题
起止时间：
2020-10-01 至 2022-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=436100&lang=en
关键词：
Brain Cholesterol Metabolism Cellular Models Of Prion Disease Cholesterol 24-Hydroxylase (Cyp46a1) Cyp46a1 Activator (Efavirenz) Mouse Models Of Human Prion Disease Neurodegenerative Diseases Neuroscience Prion Disease Repurposed Drug, Efavirenz

项目摘要

项目成果

Ali Tahir的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Prion diseases are a group of infectious and incurable neurodegenerative disorders that affect humans and animals. Creutzfeldt-Jakob disease (CJD) is the most common human prion disease. Animal prion diseases include scrapie in sheep/goat and mad cow dise
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of the brain-specific cholesterol hydroxylase Cyp46A1 as a novel approach for the treatment of prion diseases
  • 批准号：
    454456
  • 项目类别：
    Fellowship Programs
  • 资助金额：
    $3.28万
  • 财政年份：
    2021
  • 负责人：
    Ali Tahir
  • 依托单位：
    University of Calgary
Brain-specific enzyme cholesterol 24-hydroxylase (Cyp46A1) as a novel therapeutic target in human prion diseases
  • 批准号：
    440680
  • 项目类别：
    Fellowship Programs
  • 资助金额：
    $9.83万
  • 财政年份：
    2020
  • 负责人：
    Ali Tahir
  • 依托单位：
    University of Calgary